Methods for treating ocular inflammatory diseases
A method of treating non-infectious, inflammatory blepharitis includes administering to the affected eye of a subject an effective amount of an active ingredient in an ophthalmically acceptable vehicle for a sufficient period of time to treat the non-infectious, inflammatory blepharitis. The active ingredient consists essentially of a glucocorticoid in an ophthalmically acceptable vehicle that includes an aqueous polymer suspension that when mixed with tear fluid provides a sustained release of said active ingredient. The aqueous polymer suspension includes a carboxyl-containing polymer having less than about 5% by weight cross-linking agent and has a viscosity in a range from about 1,000 to about 30,000 centipoises. A kit includes: (a) a composition comprising about 0.1% by weight dexamethasone in this ophthalmically acceptable vehicle and (b) instructions for using the composition of (a) for the treatment of blepharitis.
1. A method for treating non-infectious, inflammatory blepharitis by identifying an individual with non-infectious, inflammatory blepharitis and topically administering a formulation consisting of a glucocorticoid in an ophthalmically acceptable vehicle for a sufficient period of time to treat blepharitis, wherein the ophthalmically acceptable vehicle contains an aqueous polymer suspension of a carboxyl-containing-polymer having less than about 5% by weight cross-linking agent and viscosity in a range from about 1,000 to about 30,000 centipoises and wherein the formulation when administered to the eye provides a sustained release of the glucocorticoid, and wherein the method does not comprise administration of an antibiotic.
2. The method of claim 1 , wherein the glucocorticoid is selected from the group consisting of hydrocortisone, cortisone acetate, prednisone, prednisolone, methylprednisolone, dexamethasone, betamethasone, triamcinolone, and beclometasone, fluorometholone.
3. The method of claim 2 , wherein the glucocorticoid is dexamethasone.
4. The method of claim 1 , wherein the glucocorticoid is present in a range from about 0.05% and to about 0.5% by weight.
5. The method of claim 4 , wherein the glucocorticoid is present in a range from about 0.08% to about 0.12% by weight.
6. The method of claim 3 , wherein the glucocorticoid is present in at about 0.1% by weight.
7. The method of claim 1 , wherein said ophthalmically acceptable vehicle further comprises a preservative.
8. The method of claim 1 , wherein said preservative comprises benzalkonium chloride.
9. The method of claim 8 , wherein said preservative is present in a range from about 0.001 to about 0.005% by weight.
10. The method of claim 1 , wherein the average particle size of the carboxyl-containing-polymer particles is in the range of 6 μm to 50 μm.
11. The method of claim 1 , wherein the carboxyl-containing-polymer is present from about 0.1% to about 6.5% by weight, based on the total weight of the suspension.
12. The method of claim 1 , wherein the pharmaceutical formulation further comprises a second polymer as a viscosifier.
13. The method of claim 12 , wherein the second polymer is chitosan or a chitosan salt in an amount from about 0.01% to 0.5% by weight.
14. The method of claim 13 , wherein chitosan or chitosan salt has a molecular weight in a range from between about 50 kDa to about 100 kDa.
15. The method of claim 13 , wherein chitosan or chitosan salt has a molecular weight in a range from between about 1000 kDa to about 3000 kDa.
16. The method according to claim 1 , where the origin of blepharitis is not related to bacteria.